Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The bleeding time in pediatrics.

A H Sutor1

  • 1Universitäts-Kinderklinik, Freiburg, Germany.

Seminars in Thrombosis and Hemostasis
|March 5, 1999
PubMed
Summary
This summary is machine-generated.

The bleeding time (BT) test assesses primary hemostasis and is valuable for diagnosing bleeding disorders, especially in pediatrics. When prolonged, it indicates potential defects in platelets or clotting factors, guiding therapy and surgical risk assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening children with thrombosis for thrombophilic proteins. Cui bono?

Journal of thrombosis and haemostasis : JTH·2003
Same author

[Catheter-related thrombosis and its prevention in infancy].

Hamostaseologie·2003
Same author

Pro- and anticoagulatory factors under sodium valproate-therapy in children.

Neuropediatrics·2002
Same author

Problems with platelet counting in thrombocytopenia. A rapid manual method to measure low platelet counts.

Seminars in thrombosis and hemostasis·2001
Same author

Acute immune thrombocytopenia (ITP) in childhood: retrospective and prospective survey in Germany.

Seminars in thrombosis and hemostasis·2001
Same author

Function of von Willebrand factor in children with diarrhea-associated hemolytic-uremic syndrome (D+ HUS).

Seminars in thrombosis and hemostasis·2001
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Area of Science:

  • Hematology
  • Clinical Pathology
  • Pediatric Medicine

Background:

  • The bleeding time (BT) test evaluates primary hemostasis, influenced by platelets, blood cells, vascular factors, hormones, and temperature.
  • Variations within normal limits are physiologically expected and clinically insignificant.

Observation:

  • Prolonged BT values, exceeding the upper normal limit, suggest potential defects in primary hemostasis.
  • These defects may include thrombocytopenia, thrombocytopathy, anemia, leukopenia, or deficiencies in factors like von Willebrand factor (vWF).

Findings:

  • The BT serves as a valuable screening test for patients presenting with bleeding symptoms.
  • It is particularly informative in pediatrics, where primary hemostasis defects are more prevalent than coagulopathies.

Related Experiment Videos

  • The BT can guide therapeutic interventions by reflecting clinical improvement.

    • Implications:

    • When used preoperatively, BT should be complemented by activated partial thromboplastin time (aPTT) to detect coagulopathies.
    • Standardized BT offers a reliable method for diagnosing hemostatic disorders, guiding treatment, and anticipating surgical bleeding risks.
    • Its suitability for pediatrics stems from minimal blood requirement, avoidance of venipuncture, immediate results, and in vivo assessment of primary hemostasis.